The Journal of Nutritional Biochemistry
Volume 21, Issue 3 , Pages 237-246 , March 2010

Zinc supplementation partially prevents renal pathological changes in diabetic rats

  • Yunan Tang

      Affiliations

    • The Chinese-American Research Institute for Diabetic Complications, The Wenzhou Medical College, Wenzhou, China
    • Department of Pediatrics, The University of Louisville, Louisville, KY 40202, USA
    • Equal contribution to this work.
    • ,
  • Qin Yang

      Affiliations

    • Department of Pathophysiology, Guiyang Medical College, Guiyang 55000, China
    • Corresponding Author InformationCorresponding authors. Qin Yang is to be contacted at Department of Pathophysiology, Guiyang Medical College, Guiyang, China. Lu Cai, at The Department of Pediatrics, University of Louisville, 570 S. Preston St, Baxter I Building, Suite 304F, Louisville, KY 40202, USA.
    • Equal contribution to this work.
    • ,
  • Jiayin Lu

      Affiliations

    • The China-Japan Union Hospital of Jilin University, Changchun, China
    • ,
  • Xiaolin Zhang

      Affiliations

    • Department of Pathophysiology, Guiyang Medical College, Guiyang 55000, China
    • ,
  • Di Suen

      Affiliations

    • Department of Pathophysiology, Guiyang Medical College, Guiyang 55000, China
    • ,
  • Yi Tan

      Affiliations

    • The Chinese-American Research Institute for Diabetic Complications, The Wenzhou Medical College, Wenzhou, China
    • Department of Pediatrics, The University of Louisville, Louisville, KY 40202, USA
    • ,
  • Litai Jin

      Affiliations

    • The Chinese-American Research Institute for Diabetic Complications, The Wenzhou Medical College, Wenzhou, China
    • ,
  • Jian Xiao

      Affiliations

    • The Chinese-American Research Institute for Diabetic Complications, The Wenzhou Medical College, Wenzhou, China
    • ,
  • Rujia Xie

      Affiliations

    • Department of Pathophysiology, Guiyang Medical College, Guiyang 55000, China
    • ,
  • Madhavi Rane

      Affiliations

    • The Chinese-American Research Institute for Diabetic Complications, The Wenzhou Medical College, Wenzhou, China
    • Department of Pediatrics, The University of Louisville, Louisville, KY 40202, USA
    • ,
  • Xiaokun Li

      Affiliations

    • The Chinese-American Research Institute for Diabetic Complications, The Wenzhou Medical College, Wenzhou, China
    • ,
  • Lu Cai

      Affiliations

    • The Chinese-American Research Institute for Diabetic Complications, The Wenzhou Medical College, Wenzhou, China
    • Department of Pediatrics, The University of Louisville, Louisville, KY 40202, USA
    • Departments of Radiation Oncology and Pharmacology and Toxicology, The University of Louisville, Louisville, KY 40202, USA
    • Corresponding Author InformationCorresponding authors. Qin Yang is to be contacted at Department of Pathophysiology, Guiyang Medical College, Guiyang, China. Lu Cai, at The Department of Pediatrics, University of Louisville, 570 S. Preston St, Baxter I Building, Suite 304F, Louisville, KY 40202, USA.

Received 15 August 2008 ,Revised 28 November 2008 ,Accepted 3 December 2008.

References 

  1. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11:2279–2299
  2. Ahmad FK, He Z, King GL. Molecular targets of diabetic cardiovascular complications. Curr Drug Targets. 2005;6:487–494
  3. Jay D, Hitomi H, Griendling KK. Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med. 2006;40:183–192
  4. Brandao-Neto J, Silva CA, Shuhama T, Silva JA, Oba L. Renal handling of zinc in insulin-dependent diabetes mellitus patients. Biometals. 2001;14:75–80
  5. Batista MN, Cuppari L, de Fatima Campos Pedrosa L, Almeida MG, de Almeida JB, de Medeiros AC, et al. Effect of end-stage renal disease and diabetes on zinc and copper status. Biol Trace Elem Res. 2006;112:1–12
  6. Soinio M, Marniemi J, Laakso M, Pyorala K, Lehto S, Ronnemaa T. Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care. 2007;30:523–528
  7. Song Y, Wang J, Li XK, Cai L. Zinc and the diabetic heart. Biometals. 2005;18:325–332
  8. Alscher DM, Braun N, Biegger D, Stuelten C, Gawronski K, Murdter TE, et al. Induction of metallothionein in proximal tubular cells by zinc and its potential as an endogenous antioxidant. Kidney Blood Press Res. 2005;28:127–133
  9. Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation. 2006;113:544–554
  10. Nordberg GF, Goyer R, Nordberg M. Comparative toxicity of cadmium-metallothionein and cadmium chloride on mouse kidney. Arch Pathol. 1975;99:192–197
  11. Cacini W, Singh Y. Renal metallothionein and platinum levels in diabetic and nondiabetic rats injected with cisplatin. Proc Soc Exp Biol Med. 1991;197:285–289
  12. Jin T, Nordberg GF, Sehlin J, Leffler P, Wu J. The susceptibility of spontaneously diabetic mice to cadmium-metallothionein nephrotoxicity. Toxicology. 1994;89:81–90
  13. Cai L, Chen S, Evans T, Cherian MG, Chakrabarti S. Endothelin-1-mediated alteration of metallothionein and trace metals in the liver and kidneys of chronically diabetic rats. Int J Exp Diabetes Res. 2002;3:193–198
  14. Zalups RK, Cherian MG. Renal metallothionein metabolism after a reduction of renal mass. II. Effect of zinc pretreatment on the renal toxicity and intrarenal accumulation of inorganic mercury. Toxicology. 1992;71:103–117
  15. Sharma R, Sharma M, Datta PK, Savin VJ. Induction of metallothionein-I protects glomeruli from superoxide-mediated increase in albumin permeability. Exp Biol Med (Maywood). 2002;227:26–31
  16. Iqbal M, Noor R, Mizuno R, Okada S. Protective role of zinc-metallothionein (Zn-MT) in iron nitrilotriacetate (Fe-NTA)-induced renal oxidative damage. Redox Rep. 2003;8:163–167
  17. Song Y, Li C, Cai L. Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. Exp Mol Pathol. 2004;76:66–75
  18. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K, et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol. 2003;14:2833–2842
  19. Racusen LC, Monteil C, Sgrignoli A, Lucskay M, Marouillat S, Rhim JG, et al. Cell lines with extended in vitro growth potential from human renal proximal tubule: characterization, response to inducers, and comparison with established cell lines. J Lab Clin Med. 1997;129:318–329
  20. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. 2002;51:1938–1948
  21. Nakagawa T, Lan HY, Glushakova O, Zhu HJ, Kang DH, Schreiner GF, et al. Role of ERK1/2 and p38 mitogen-activated protein kinases in the regulation of thrombospondin-1 by TGF-beta1 in rat proximal tubular cells and mouse fibroblasts. J Am Soc Nephrol. 2005;16:899–904
  22. Sakai N, Wada T, Furuichi K, Iwata Y, Yoshimoto K, Kitagawa K, et al. Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am J Kidney Dis. 2005;45:54–65
  23. Sarkozi R, Miller B, Pollack V, Feifel E, Mayer G, Sorokin A, et al. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells. J Cell Physiol. 2007;211:88–100
  24. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol. 2006;17:2999–3012
  25. Lee HB, Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology (Carlton). 2005;10(Suppl):S11–S13
  26. Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med. 2003;115(Suppl 8A):62S–68S
  27. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP. Plasminogen activator inhibitor Type 1 is a potential target in renal fibrogenesis. Kidney Int. 2000;58:1841–1850
  28. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am J Pathol. 2004;165:2033–2043
  29. Okada H, Kikuta T, Kobayashi T, Inoue T, Kanno Y, Takigawa M, et al. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol. 2005;16:133–143
  30. Guha M, Xu ZG, Tung D, Lanting L, Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of Type 1 and Type 2 diabetes. Faseb J. 2007;
  31. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008;57:1446–1454
  32. Cai L, Wang J, Li Y, Sun X, Wang L, Zhou Z, et al. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes. 2005;54:1829–1837
  33. Cai L. Diabetic cardiomyopathy and its prevention by metallothionein: experimental evidence, possible mechanisms and clinical implications. Curr Med Chem. 2007;14:2193–2203
  34. Cai L, Cherian MG. Zinc-metallothionein protects from DNA damage induced by radiation better than glutathione and copper- or cadmium-metallothioneins. Toxicol Lett. 2003;136:193–198
  35. Cai L, Klein JB, Kang YJ. Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage. J Biol Chem. 2000;275:38957–38960
  36. Song Y, Wang J, Li Y, Du Y, Arteel GE, Saari JT, et al. Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury. Am J Pathol. 2005;167:17–26
  37. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, Epstein PN. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes. 2002;51:174–181
  38. Cheng B, Liu HW, Fu XB, Sun TZ, Sheng ZY. Recombinant human platelet-derived growth factor enhanced dermal wound healing by a pathway involving ERK and c-fos in diabetic rats. J Dermatol Sci. 2007;45:193–201
  39. Ceylan-Isik AF, LaCour KH, Ren J. Sex difference in cardiomyocyte function in normal and metallothionein transgenic mice: the effect of diabetes mellitus. J Appl Physiol. 2006;100:1638–1646
  40. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol. 2006;48:1688–1697
  41. DeRubertis FR, Craven PA, Melhem MF. Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: effects of tempol. Metabolism. 2007;56:1256–1264
  42. Mollsten A, Marklund SL, Wessman M, Svensson M, Forsblom C, Parkkonen M, et al. A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. Diabetes. 2007;56:265–269
  43. Craven PA, Melhem MF, Phillips SL, DeRubertis FR. Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes. 2001;50:2114–2125
  44. Brezniceanu ML, Liu F, Wei CC, Tran S, Sachetelli S, Zhang SL, et al. Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int. 2007;71:912–923
  45. Kedziora-Kornatowska K, Szram S, Kornatowski T, Szadujkis-Szadurski L, Kedziora J, Bartosz G. Effect of vitamin E and vitamin C supplementation on antioxidative state and renal glomerular basement membrane thickness in diabetic kidney. Nephron Exp Nephrol. 2003;95:e134–e143
  46. Huang JS, Chuang LY, Guh JY, Huang YJ, Hsu MS. Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells. Am J Physiol Renal Physiol. 2007;
  47. Anderson RA, Roussel AM, Zouari N, Mahjoub S, Matheau JM, Kerkeni A. Potential antioxidant effects of zinc and chromium supplementation in people with Type 2 diabetes mellitus. J Am Coll Nutr. 2001;20:212–218
  48. Minami T, Ichii M, Okazaki Y, Kubo M, Kadota E, Inoue T, et al. Renal changes of streptozotocin-induced diabetic rats fed a low-zinc diet. Ren Fail. 1995;17:349–363
  49. Cai L, Cherian MG, Iskander S, Leblanc M, Hammond RR. Metallothionein induction in human CNS in vitro: neuroprotection from ionizing radiation. Int J Radiat Biol. 2000;76:1009–1017
  50. Cai L, Iskander S, Cherian MG, Hammond RR. Zinc- or cadmium-pre-induced metallothionein protects human central nervous system cells and astrocytes from radiation-induced apoptosis. Toxicol Lett. 2004;146:217–226
  51. Zheng S, Carlson EC, Yang L, Kralik PM, Huang Y, Epstein PN. Podocyte-Specific Overexpression of the Antioxidant Metallothionein Reduces Diabetic Nephropathy. J Am Soc Nephrol. 2008;
  52. Devirgiliis C, Zalewski PD, Perozzi G, Murgia C. Zinc fluxes and zinc transporter genes in chronic diseases. Mutat Res. 2007;622:84–93
  53. Maret W. A role for metallothionein in the pathogenesis of diabetes and its cardiovascular complications. Mol Genet Metab. 2008;94:1–3
  54. Quraishi I, Collins S, Pestaner JP, Harris T, Bagasra O. Role of zinc and zinc transporters in the molecular pathogenesis of diabetes mellitus. Med Hypotheses. 2005;65:887–892
  55. Farvid MS, Jalali M, Siassi F, Hosseini M. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in Type 2 diabetes. Diabetes Care. 2005;28:2458–2464
  56. Kadhim HM, Ismail SH, Hussein KI, Bakir IH, Sahib AS, Khalaf BH, et al. Effects of melatonin and zinc on lipid profile and renal function in Type 2 diabetic patients poorly controlled with metformin. J Pineal Res. 2006;41:189–193
  57. Parham M, Amini M, Aminorroaya A, Heidarian E. Effect of zinc supplementation on microalbuminuria in patients with Type 2 diabetes: a double blind, randomized, placebo-controlled, cross-over trial. Rev Diabet Stud. 2008;5:102–109
  58. Al-Maroof RA, Al-Sharbatti SS. Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of Type 2 diabetics. Saudi Med J. 2006;27:344–350
  59. Gupta R, Garg VK, Mathur DK, Goyal RK. Oral zinc therapy in diabetic neuropathy. J Assoc Physicians India. 1998;46:939–942

☆ Financial support: The study was supported in part by grants from American Diabetes Association (02-07-JF-02; 05-07-02, to L. Cai), from Juvenile Diabetes Research Foundation, International (5-2006-382) and from the Chinese-American Research Institute for Diabetic Complications, Wenzhou Medical College to L. Cai and X.K. Li.

PII: S0955-2863(08)00268-4

doi: 10.1016/j.jnutbio.2008.12.010

The Journal of Nutritional Biochemistry
Volume 21, Issue 3 , Pages 237-246 , March 2010

Article Tools

* Image Usage & Resolution